The inclusion of telomerase inhibitors in chemotherapy protocols for cancer patients may have strong effects on cell proliferation and survival and thus may represent a valid strategy to complement current treatment modalities, as also suggested by others.42, 43 Confirmation of these findings in primary tumors cells from patients with EBV-driven and unrelated B-cell malignancies and in suitable animal models will pave the way for a solidly based pre-clinical rationale for including TERT inhibitors in chemotherapy protocols for the treatment of these malignancies. The gene discussed is TERT; the disease is cancer.